checkAd
    Startseite > Aktien > Panbela Therapeutics > Nachrichten
    Panbela Therapeutics Aktie
    0,4000
     
    USD
    -9,25 %
    -0,0408 USD
    Letzter Kurs 02:10:00 Nasdaq OTC
    ISIN: US69833W4042 · WKN: A4017G · SYM: PBLA · USA

    Neueste Nachrichten

    Panbela Provides Business Update and Reports Q1 2024 Financial Results
    15.05.24 · globenewswire · Panbela Therapeutics
    Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
    06.05.24 · globenewswire · Panbela Therapeutics
    Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
    01.05.24 · globenewswire · Panbela Therapeutics
    Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
    30.04.24 · globenewswire · Panbela Therapeutics
    Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
    22.04.24 · globenewswire · Panbela Therapeutics
    Panbela Announces Poster Presentation at American Association for Cancer Research:
    18.04.24 · globenewswire · Panbela Therapeutics
    Panbela Announces Transfer to OTCQB Market
    16.04.24 · globenewswire · Panbela Therapeutics
    Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
    26.03.24 · globenewswire · Panbela Therapeutics
    Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
    12.03.24 · globenewswire · Panbela Therapeutics
    Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
    15.02.24 · globenewswire · Panbela Therapeutics
    Panbela Announces Closing of Approximately $9.0 Million Public Offering
    01.02.24 · globenewswire · Panbela Therapeutics
    Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
    30.01.24 · globenewswire · Panbela Therapeutics